Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of a New Leuprolide Acetate 3.75 mg Depot Formulation, GP-Pharm S.A., When Given as Palliative Treatment to Prostate Cancer Patients

NCT00128531 is registered in ClinicalTrials.gov with GP-Pharm as lead sponsor.

NCT NCT00128531
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00128531 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of a New Leuprolide Acetate 3.75 mg Depot Formulation, GP-Pharm S.A., When Given as Palliative Treatment to Prostate Cancer Patients
Lead sponsor
GP-Pharm
Phase
Phase 3
Overall status
Completed
Start date
September 30, 2005
Completion date
November 30, 2007
Enrollment
120
Sites
28

Conditions

As the registry lists them; a condition with its own page is linked.

prostate cancer